Bridging the Poles - What the Transcranial Magnetic Stimulation Evidence Tells Us About Bipolar Depression

Sep 28, 2026

Uploaded by Marglet

Bipolar depression remains difficult to treat, with limited response and side effects from pharmacotherapy plus the complication of antidepressant-triggered mood polarity switching. In this commentary, Ventura et al. synthesize TMS evidence for bipolar depression, finding a moderate, statistically significant antidepressant effect of active TMS versus sham and no increased risk of manic or hypomanic switching. The review also details stimulation-parameter heterogeneity, limited head-to-head comparisons, and methodological constraints, while arguing that TMS offers feasible, tolerable, evidence-based clinical value.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

Background and clinical challenge

TMS evidence synthesis and efficacy

Safety findings regarding mood switching

Methodological variability and research gaps

Conceptual implications and clinical relevance

Commentary Biological Psychiatry: GOS Bridging the Poles: What the Transcranial Magnetic Stimulation Evidence Tells Us About Bipolar Depression Véronique Desbeaumes Jodoin Bipolar depression remains one of the most therapeutically challenging phases of mood disorders. Despite substantial progress in pharmacotherapy, many patients experience inadequate response or side effects, and the risk of mood polarity switching complicates antidepressant use. In contrast, transcranial magnetic stimulation (TMS) has emerged as a safe and effective neuromodulatory treatment for unipolar major depression, now widely implemented across clinical settings (1 ,2) . However, its role in bipolar depression has long been underexplored, hindered by small trials, heterogeneous methodologies, and enduring safety concerns regarding treatment-emergent mania. In this context, the recent systematic review and metaanalysis by Ventura et al. (3) in Biological Psychiatry: Global Open Science provides the most comprehensive synthesis to date of the efficacy, effectiveness, and safety of TMS in bipolar depression. By compiling data across stimulation modalities and clinical contexts, their work addresses a crucial gap in the literature and invites a broader reflection on how neuromodulation fits within the therapeutic framework of bipolar depression, moving from categorical exclusion toward evidence-based inclusion. The authors’ analysis demonstrates a moderate and statistically significant antidepressant effect of active TMS compared with sham, with standardized mean differences in the range of 0.4 to 0.6, comparable with the effect sizes that have typically been reported for pharmacological antidepressants in bipolar depression. However, direct comparisons remain limited, as few head-to-head trials have evaluated TMS against established pharmacotherapies, which itself represents a gap for future research (1 ,4) . Importantly, no increased risk of manic or hypomanic switching was detected, an observation that is consistent with consensus data indicating only isolated cases of treatment-emergent mania, typically under left-sided high-frequency stimulation (4) . Collectively, these findings challenge longstanding cautionary views and support the broader, evidence-based clinical use of TMS in bipolar depression. The authors also emphasize the heterogeneity of stimulation parameters, including target sites (most frequently the left dorsolateral prefrontal cortex), frequency, and treatment duration. However, across modalities, results consistently favored active stimulation. By synthesizing findings from both controlled and open-label designs, Ventura et al. (3) move beyond early proof-of-concept trials to demonstrate the broader feasibility and tolerability of TMS in bipolar depression. These findings echo recent real-world data including both unipolar and bipolar treatment-resistant depression populations, which have shown the effectiveness and tolerability of accelerated TMS protocols in clinical settings (5) . Collectively, their findings help clarify that bipolar depression, long treated as an exception in neuromodulation research, responds to TMS with an efficacy comparable with that observed in unipolar depression. While Ventura et al. (3) convincingly establish that TMS exerts therapeutic benefit in bipolar depression, their metaanalysis also highlights important methodological constraints. Protocols varied in stimulation intensity, number of sessions, and maintenance schedules, while diagnostic criteria often combined bipolar I and II disorders without stratified analyses. Such variability may obscure potential differences in treatment response across subtypes, illness phases, or concomitant medication regimens. More broadly, the existing evidence base is limited by small sample sizes, modest blinding integrity, and inconsistent sham conditions, all of which may compromise reproducibility. The inclusion of both repetitive TMS and deep

FAQs

What clinical problem does this commentary address?

Bipolar depression is portrayed as therapeutically challenging due to inadequate responses to pharmacotherapy, side effects, and the risk of mood polarity switching that complicates antidepressant use.

What does the systematic review conclude about TMS efficacy in bipolar depression?

Active TMS shows a moderate and statistically significant antidepressant effect versus sham, with standardized mean differences in the range of 0.4 to 0.6.

Does the evidence suggest TMS increases the risk of mania or hypomanic switching?

No increased risk is detected; treatment-emergent mania appears to occur only in isolated cases, often linked to left-sided high-frequency stimulation.

Sep 28, 2026

Uploaded by Marglet